anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The association between sarcopenia and cardiovascular disease (CVD) is well known. However, the clinical diagnosis of sarcopenia is complex and not suitable for early clinical identification and prevention of CVD. Relative muscle strength (RMS) is a relatively quantitative and straightforward indicator, but its association with CVD remains unclear. Hence, the objective of this research was to investigate the correlation between RMS and CVD incidence.
METHODS: This was a cross-sectional study, using data from the China Health and Retirement Longitudinal Study (CHARLS) in 2011. CVD events were assessed through self-reported physician diagnoses. The RMS was determined by dividing the maximum grip strength by the appendicular skeletal muscle mass (ASM). This study used multivariate logistic regression and restricted cubic spline (RCS) curves to explore the correlation between RMS and CVD incidence. Additionally, we conducted subgroup analyses to provide additional evidence supporting the association between the two variables.
RESULTS: A total of 8,733 people were included in our study, with 1,152 (13.19%) CVD patients and 7,581 (86.81%) non-CVD patients. When the data were grouped according to quartiles (Q) of RMS, the inverse association between CVD and RMS remained statistically significant even after controlling for all potential confounding factors. Compared with participants in Q1 of RMS, the ORs (95% CIs) of CVD among those in Q2-Q4 were 0.99 (0.83, 1.17), 0.81 (0.67, 0.98), and 0.70 (0.57, 0.85), respectively. Moreover, the RCS results showed a negative linear correlation between the RMS and CVD incidence (P for nonlinearity = 0.555). Subgroup analysis revealed no significant interaction in any of the groups except for the sex group (P for interaction = 0.046).
CONCLUSION: Our study indicated a stable negative correlation between RMS and CVD incidence. RMS is helpful for the early identification and prevention of CVD.
Compounds represented by general formula [I] or pharmaceutically acceptable salts thereof; a process for producing the same; and remedies for diabetes, preventives for complication of diabetes or antiobestic agents containing as the active ingredient the above compounds or pharmaceutically acceptable salts thereof in said formula,R represents azido, etc.; R1 and R2 are the same or different and each represents hydrogen, etc.; R3 and R4 are the same or different and each represents hydrogen, etc.; X1 represents oxygen, etc.; X2 represents oxygen, etc.; Y represents oxygen, etc.; and Z represents fused aryl, etc.
BACKGROUND: The high prevalence of sleep problems and their negative consequences on children and parents highlight the need to design early screening instruments to evaluate sleep problems in early childhood. We aimed to determine the validity and reliability of the Brief Infant Sleep Questionnaire (BISQ) among the Iranian population.
METHODS AND MATERIALS: This study included 646 one-year-old infants by random sampling from the PERSIAN birth cohort study. Following the forward-backward translation of the BISQ, its psychometric properties, including construct validity in terms of concurrent and convergent validities as well as reliability, were evaluated.
RESULTS: The CVIs and CVR ranged between 0.8 and 1.00 for all items. Therefore, we keep all the items of the original version of the BISQ in the Persian BISQ. Concurrent validity was assessed by comparing items of the Persian BISQ among different maternal views regarding their infant's sleep. All BISQ items were significantly different among the two levels of maternal view about the infant's sleep problem except daytime sleep duration. The convergent validity of the BISQ was evaluated by calculating the correlation between BISQ items and the ISQ (infant sleep questionnaire) total score as a similar tool. ISQ score was adequately correlated with nocturnal sleep latency and the number of waking at night (rs ranged from 0.59 to 0.72). In addition, the associations of mothers' and infants' demographic variables and nutritional and gestational variables with BISQ items were presented to confirm construct validity. Strong correlations were found between the repeated sleep measures for sleep arrangement, sleep position, and sleep situation (kappa ranged from 0.65 to 0.84), nocturnal sleep duration, daytime sleep duration number of wakings at night, night waking duration, nocturnal sleep latency and sleep-onset time (ICC ranged 0.91 to 0.99).
CONCLUSION: The Persian version of the BISQ is a reliable and valid measure for assessing sleep problems in infants. It would be helpful to be utilized for the early diagnosis of infants' sleep problems.
The invention relates to the field of veterinary biological products and is aimed at providing a veterinary vaccine immunologic adjuvant as well as a preparation and application method thereof. The adjuvant is prepared by mixing water-soluble calcium carbonate, polysorbate 80, 2-phenoxy ethanol, chitosan oligosaccharide, xanthan gum and deionized water, wherein the weight ratio of the water-soluble calcium carbonate to deionized water is 0.001-0.01%; the volume ratio of the polysorbate 80 to deionized water is 1-10%; the final concentration of the 2-phenoxy ethanol is 0.5-2.5% (volume ratio); the final concentration of the chitosan oligosaccharide is 0.5-2% (weight ratio); the final concentration of the xanthan gum is 0.1-2% (weight ratio). The adjuvant provided by the invention can enhance the identification ability of lymphocytes for the A, B and H antigens, promote the combination of multiple antigens with an antibody and enhance the immune response level and antigen presentation ability. The adjuvant is kept in a steady state at low temperature and room temperature; due to the antibacterial ability, secondary infection after immunization is avoided. The adjuvant is easy to prepare and thus can be stored for long time at room temperature. The cost of raw materials is low, and the adjuvant is suitable for large-area promotion and application.
PURPOSE: A composition containing extract of Agaricus bisporus mycelium or fruit body is provided to enhance anti-aging and anti-wrinkling. CONSTITUTION: A cosmetic composition for anti-aging and anti-wrinkling contains extract of Agaricus bisporus mycelium or fruit body as an active ingredient. The deposit number of Agaricus bisporus is IUM03418(strain and DNA genebank deposit number). A pharmaceutical composition for anti-aging and anti-wrinkling contains the extract as an active ingredient. A neutraceutical for anti-aging and anti-wrinkling contains the extract as an active ingredient. The cosmetic composition is manufactured in the form of skin lotion, skin softener, skin toner, astringent, lotion, hand cream, foundation, essence, pack, soap, and cleansing foam.
Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel associations between p97 and other proteins, including UBX-domain-containing proteins (UBX-polypeptides), HIF1α, and a variety of E3 ligases are provided herein. The disclosure provides complexes comprising UBX-domain-containing polypeptides (UBX-polypeptides) and other polypeptides involved in the degradation of ubiquitinated proteins. In addition, the disclosure provides uses for active agents that modulate protein-protein complex formation between an UBX-polypeptide and its complementary-binding substrate. For example, the disclosure provides methods for treating or preventing hypoxia-related disorders or conditions in a patient or a cell by administration of an active agent that modulates the activity of an UBX-polypeptide and/or its complementary binding-substrate. Furthermore, the disclosure provides uses for active agents that modulate HIF1α activity; such agents may be used to modulate processes that are regulated by HIF1α. The disclosure also provides many screening assays to identify test agents that modulate complex formation between an UBX-polypeptide and its complementary-binding substrate or methods for evaluating modes of action and/or effects of active agents that have already been identified as modulators of an UBX-polypeptide and/or its complementary-binding substrate.
The invention discloses a traditional Chinese medicine composition for preventing and treating avian influenza and its preparation method and use, and belongs to the technical field of veterinary traditional Chinese medicines and livestock feed additives. The traditional Chinese medicine composition comprises, by weight, 2-10 parts of herba houttuyniae, 5-10 parts of polygonatum rhizome, 10-15 parts of centella asiatica, 10-30 parts of tuber of dwarf lilyturf, 5-10 parts of coptis root, 10-20 parts of plantain herb, 5-10 parts of Lysimachia congestifloraHemsl., 5-10 parts of red sage root, 2-5 parts of fruit of Chinese magnoliavine and 10-30 parts of flower of poplar. Ten pure natural Chinese herbal medicines such as herba houttuyniae, polygonatum rhizome, centella asiatica and the like are matched according to a monarch-minister-adjuvant-messenger principle. The above raw materials have wide sources, a low cost, safety, reliability and no toxic or side effect and have effects of preventing and treating avian influenza and improving animal immunity and adaptability. The preparation method has simple processes and can be operated easily. The traditional Chinese medicine composition has an avian influenza prevention and treatment protection rate more than 80%.
FIELD: molecular biology, medicine, endocrinology. SUBSTANCE: invention relates to glucagon receptors. Invention proposes the isolated DNA molecule encoding glucagon receptors or glucagon peptide receptors. DNA-construction provides expression of isolated DNA molecule and its insertion into cells of lines COS or BHK. Invention proposes also a method of preparing glucagon receptors involving culturing cell lines COS or BHK and isolation of the end product. Invention presents also a monoclonal antibody binding specifically with glucagon receptors and blocking glucagon binding with glucagon receptors. Invention relates to also a method of detection of glucagon antagonist involving agonist binding with isolated glucagon receptors. Invention can be associated with stimulation of glycolysis and glycogenolysis and study of glucagon role in diabetes mellitus etiology. EFFECT: improved method of preparing DNA, glucagon and peptide receptors. 13 cl, 5 dwg, 8 tbl
Gemifloxacin compounds are used to modulate the metabolism of respiratory tract pathogenic bacteria, and to treat and prevent infection by such bacteria. Independent claims are included for: (1) modulating metabolism of respiratory tract pathogenic bacteria, comprising contacting the bacteria with a composition comprising a gemifloxacin compound, or derivative of this; and (2) treating or preventing infection by respiratory tract pathogenic bacteria, comprising administering a gemifloxacin compound to a mammal. ACTIVITY : Antibacterial. In tests, gemifloxacin exhibited activity against S. pneumoniae, with MIC90 values of 0.03 Microg/ml for both penicillin-susceptible and penicillin-resistant strains. It was active against S. aureus, with MIC90 values of 0.03 Microg/ml for methicillin-resistant strains. It was active against all isolates of H. influenzae and M. catarrhalis tested, with MIC90 values of 0.008 Microg/ml for at least some of these. MECHANISM OF ACTION : None given.
All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
Participants will receive a single dose of VX-993 on Day 1 and Itraconazole once daily (qd) on Days 7 through Day 15. On Day 10 participants will receive Itraconazole followed by VX-993.
In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
This trial was conducted between October 2015 and June 2017 at the Miaoli General Hospital in Taiwan, and all eligible participants signed informed consent. The eligible pre-frail or frail elderly were screened according to the frailty phenotypes proposed by Fried and colleagues in the outpatient clinics. Participants who were over 65 years old and were able to walk 14 m independently were eligible for recruitment. The main exclusion criteria were critical illnesses; impairment in communication; nursing-home residents; participating other studies or taking nutritional supplementation; severe depression (Geriatric Depression Scale (GDS) \< 10 points) or cognitive impairment (Mini Mental State Examination \< 23 points). Participants were randomly assigned into study groups for 3-month intervention and 3-month self-maintenance period. The assessment of all participants were conducted by blind case managers at baseline, 1 month, 3 months, and 6 months.
Disclosed are emulsions and microcapsules that comprise one or more substances with a low interfacial tension. Methods of making the emulsions and microcapsules as well as methods of using them are also disclosed. In some embodiments microbial oil is used. In some embodiments marine oil is used. In some embodiments the emulsion has a pH of greater than 6,0. In some embodiments the emulsion has a pH of less than 5,0.
A query device for conducting automated user identification using a domain specific query language is described. The domain specific language is a computer language specially adapted for use in the healthcare domain. The domain specific language includes specific syntax suitable to the medical or healthcare industries, and is structured in the form of a string for processing. The domain-specific query is automatically processed and delineated into one or more processing sections. The domain-specific query is specifically structured for improved efficiency through iterative processing of the one or more processing sections, where each of the one or more processing sections is classified and mapped to a specific filter. Each filter represents a programmatic mechanism for automatically conducting a query against one or more backend data storages or other datasets to return a list of users or equipment that meet the criteria of the filter. Corresponding methods, and computer readable media are described.
A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA.
Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
The invention discloses a microcapsule for microwave tumor treatment, the diameter of the microcapsule is 1-20 μm, the thickness of the shell layer of the microcapsule is 0.4-4 μm; the core material is microwave heating material, and the shell material of the microcapsule is gelatin or a composite material of gelatin and chitosan. The microcapsule prepared by the invention has good microwave heating effect, is regular spherical, has high hollowness, narrow particle size distribution and controllable particle size. The method has the advantages of simple process, high generation efficiency and easy realization of large-scale production. Under the induction of microwave, the inorganic salt ions in the microcapsule generate heat through vibration, and the temperature of the tissue can be raised to more than 43 ℃ through releasing energy in a short time, so that the aim of eliminating tumor or cancer cells is fulfilled. The shell material contains a large amount of amino groups, so that the shell material has the functions of adsorption separation, catalysis, controllable drug release and the like. The gelatin and the chitosan have good biocompatibility and degradable materials, so the chitosan and the gelatin have good development prospects in clinical application.
The invention belongs to the field of pharmacology and pharmaceutics and relates to a vinpocetine fat emulsion concentrated solution, a preparation method and an application thereof. According to the invention, the defect that a traditional fat emulsion preparation technology is complex and has poor stability is overcome. The preparation technology provided by the invention is simple; the general physical stirring process is only needed; and no homogenization technology is required. A product prepared in the invention can be sterilized through a 0.22-micron microfiltration membrane; in clinical use, the product can be spontaneously emulsified after diluted by the use of an aqueous solution such as normal saline or a glucose solution, etc. and slightly oscillated; and under optimized conditions, average particle size is about 0.2 micron, and injection fat emulsion characteristics are fully embodied. The product has good fluidity, will not be retained on the wall, is single-phase, transparent and clear in appearance, can undergo clarification detection, will not cause preparation stratification after multigelation and is used in improving various symptoms induced by diseases such as sequel of cerebral infarction, cerebral hemorrhage sequelae, cerebral arteriosclerosis and the like.
The invention relates to a Tibetan medicine composition, in particular to a Tibetan medicine composition for adjusting the blood fat, and a preparation method for the composition. The composition comprises the following raw materials according to parts by weight: 50 to 150 parts of rhubarb from Rheum emodi Wall, 40 to 120 parts of hawthorn fruit and 30 to 90 parts of emblic leafflower fruit. The preparation method comprises the following steps: processing the rhubarb from Rheum emodi Wall with vinegar, selecting the raw materials, concentration, feeding, dry granulating or filtration, filling capsules or pouring. The invention takes the typical plants in Tibet as the raw material, thereby having concentrated Tibetan flavor. The invention can reduce the blood viscosity, the plasma viscosity and the content of the fibrinogen, prevent the thrombus, improve the blood flow and is safe and nontoxic. The three kinds of medicine are used together and mutually coordinated, have good therapeutic action and health-care function to the patients with hyperlipemia and the crowds with dyslipidemia and are safely used. The invention can be not only taken as medicine, but also used as the health-care products and has obvious adjusting effect to the blood fat of the human body.
A handheld diabetes management device includes a blood glucose measurement engine that measures a blood glucose level of a patient. The device includes a physical port that is exposed at an exterior of the device. The device includes a processing module that includes first, second, and third physical interfaces that are internal to the device. The device includes a multiplexing module that alternatively connects the physical port to one of the first, second, and third physical interfaces of the processing module. The processing module selectively operates the first physical interface using first and second modes. When an external host is connected to the physical port, the processing module selectively transfers information based on the blood glucose level to the external host using the first mode. When the external host is connected to the physical port, the processing module selectively provides file access to the external host using the second mode.